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Abstract:
Introduction: Stress and urgency incontinence are heritable, but no risk loci have been identified. We undertook
a GWAS, using three European cohorts, followed by replication in six further studies, with supplementary
transcriptomic analyses using human bladder biopsies.
Materials and Methods: Genotyping in discovery cohorts (n=8,979) was conducted using Illumina arrays.
Replication genotyping used competitive PCR (n=4,069). Biopsies from women with urgency or stress
incontinence were run on Affymetrix-U133 arrays.
Results: Discovery analyses identified five genome-wide significant loci. Two loci replicated: rs138724718
(p=3.39x10-09) and rs34998271 (p=1.70x10-09). In analysis of differential expression, the top-ranked process
(GO:0003012, p=7.5x10-10), includes CHRM3 (fold difference:4.23, p=0.0007), which is the main drug target for
urgency incontinence, SULF2 (fold difference:1.52, p=0.005) in the top locus from the discovery phase, and EDN1
(fold difference:-1.60, p=0.09) in the top locus from the replication phase.
Conclusions: We identified two genetic variants strongly associated with urinary incontinence. The first,
rs138724718, is situated near MARCO, with a role in host defense. The second, rs34998271, is situated near EDN1
a potent constrictor of smooth muscle, which was differentially expressed in bladder. This work highlights the
myogenic and urotheliogenic mechanisms for incontinence, and suggests the potential of endothelin modulating
drugs for urgency incontinence.
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20 46424160 rs139329202 c g 0.01 UUI 8.50 4.12-17.55 8.07x10
-9 1.35 0.82-2.21 0.238 2.38x10
-05
6 1430664 rs146033157 a t 0.03 UUI 0.33 0.23-0.48 1.73x10
-8 0.97 0.35-2.71 0.960 n/a
14 55489229 rs146757102 a g 0.05 UUI 0.45 0.34-0.60 1.95x10
-8 1.13 0.87-1.45 0.360 5.12x10
-03
7 141328145 rs78851245 t c 0.02 Any UI 3.22 2.13-4.86 2.92x10
-8 1.46 1.00-21.3 0.051 2.11x10
-07
7 34354797 rs78878767 a c 0.01 UUI 4.26 2.56-7.10 3.04x10
-8 0.86 0.51-1.43 0.556 2.11x10
-07
3 55473083 rs13059018 c g 0.07 SUI 0.70 0.61-0.81 1.01x10
-7 1.14 1.00-1.29 0.054 1.40x10
-06
12 11049362 rs201363123 ag a 0.06 Any UI 0.65 0.56-0.76 1.03x10
-7 1.14 1.00-1.29 0.053 5.43x10
-05
1 154881110 rs1218596 t c 0.06 Any UI 0.64 0.55-0.75 1.04x10
-7 0.95 0.75-1.20 0.681 4.49x10
-06
11 39642765 rs10768519 a c 0.26 UUI 0.80 0.74-0.87 2.26x10
-7 1.00 0.85-1.17 0.954 1.40x10
-04
9 105517298 rs72738866 t c 0.26 SUI 0.79 0.71-0.87 2.55x10
-7 1.01 0.89-1.14 0.895 5.97x10
-05
2 119587824 rs138724718 a g 0.02 SUI 1.85 1.47-2.35 2.89x10
-7 1.73 1.20-2.48 0.003 3.39x10
-09
6 12533066 rs34998271 a g 0.05 UUI 1.70 1.40-2.07
4.97 x10-
7 1.55
1.20-
2.01 0.0008 1.70x10
-09
ESHG Conference c/o Vienna Medical Academy
Alser Strasse 4, A-1090 Vienna, Austria
Tel: (+43/1) 405 13 83-22
Fax (+43/1) 407 82 74
Leave OASIS Feedback Leave OASIS Feedback
Powered by cOASIS, The Online Abstract Submission and Invitation System SM
© 1996 - 2017 CTI Meeting Technology All rights reserved.
:
Author Disclosure Information:
 R. Cartwright: None. M. Jarvelin: None. P. Miotla: None. V. Khullar: None. P. Bennett: None. A. Walley: None. 
Topic (Complete):  03. Internal organs & endocrinology (lung, kidney, liver, gastrointestinal) 
Keyword (Complete):  Incontinence 
Presentation Preference (Complete):  Oral preferred 
Awards - Fellowships (Complete): 
     I apply for the Young Investigator Award: Yes
     I am a: Post-doc researcher
     Date of PhD/MD - dd.mm.yyyy: : 01.04.2016
     Application for Fellowship: No
     Application for Fellowship: No
     Application for Fellowship: Yes
     
Status: Complete
